Disease: Psoriasis ×
Source: ALL
Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
CUI: C0033860
Disease: Psoriasis
Psoriasis 		0.020 Biomarker disease BEFREE Guselkumab is a subcutaneously administered monoclonal antibody that targets the IL-23p19 cytokine subunit and has been approved by the US FDA and the EMA for the treatment of moderate-to-severe psoriasis in adult patients. 30920855 2019
CUI: C0033860
Disease: Psoriasis
Psoriasis 		0.020 Biomarker disease BEFREE Brodalumab, a human antibody against IL-17 receptor A, has been approved by the US FDA in February 2017, by the Japanese Pharmaceuticals and Medical Devices Agency in July 2016 and by the EMA in July 2017 for the treatment of moderate-to-severe psoriasis. 28879789 2017